Ecliptasaponin A

Ecliptasaponin A is a triterpenoid saponin isolated from Eclipta prostrata, a plant used in traditional Ayurvedic and Chinese medicine. It primarily exerts its effects by activating apoptotic signaling cascades such as the ASK1/JNK pathway and inhibiting matrix metalloproteinases involved in tissue remodeling.

Origin & History

Ecliptasaponin A is a triterpenoid saponin (pentacyclic triterpenoid glucoside) with molecular formula C₃₆H₅₈O₉ naturally found in plants including Eclipta alba, Eclipta prostrata, and Magnolia soulangeana. It is typically isolated through extraction and purification methods such as UHPLC-DAD-Q-TOF-MS for both qualitative and quantitative analysis.

Historical & Cultural Context

No information on traditional medicinal uses or historical context is available in the research for Ecliptasaponin A specifically. While the parent plants have traditional uses, the isolated compound lacks documented historical application.

Health Benefits

• May support lung health by inducing apoptosis in lung cancer cells via ASK1/JNK pathway activation (preliminary in-vitro evidence)
• Potentially reduces pulmonary fibrosis markers by inhibiting matrix metalloproteinases and reducing oxidative stress (animal model evidence)
• May decrease inflammation by downregulating COX-2 and TGF-β1 proteins (preclinical evidence only)
• Possibly enhances antioxidant activity through increased superoxide dismutase (SOD) levels (animal studies)
• Could help regulate tissue remodeling by inhibiting MMP-2/9 and α-SMA expression (laboratory research)

How It Works

Ecliptasaponin A activates apoptosis-signal-regulating kinase 1 (ASK1) and its downstream c-Jun N-terminal kinase (JNK) pathway, promoting programmed cell death in abnormally proliferating cells. It also inhibits matrix metalloproteinases (MMP-2 and MMP-9), enzymes responsible for extracellular matrix degradation and fibrotic tissue remodeling. Additionally, it appears to suppress reactive oxygen species (ROS) generation and modulate NF-κB signaling, reducing downstream pro-inflammatory cytokine production including TNF-α and IL-6.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on Ecliptasaponin A. Current evidence is limited to preclinical studies, including in vitro research showing apoptosis induction in human lung cancer cells and animal models of bleomycin-induced pulmonary fibrosis.

Clinical Summary

Research on Ecliptasaponin A remains in early preclinical stages, with no published human clinical trials to date. In vitro studies using human lung cancer cell lines (A549 and H1299) demonstrated dose-dependent induction of apoptosis, with cell viability reductions of approximately 40–60% at concentrations of 20–50 µM. Rodent models of pulmonary fibrosis showed reductions in collagen deposition and MMP activity following administration, though translatable dosages for humans remain undefined. The overall evidence base is preliminary, and conclusions about efficacy in humans cannot yet be drawn.

Nutritional Profile

Ecliptasaponin A is a purified triterpenoid saponin compound (not a whole food or dietary ingredient), therefore it does not possess a conventional macronutrient or micronutrient profile. Structurally, it is classified as an oleanane-type pentacyclic triterpenoid saponin isolated primarily from Eclipta prostrata (false daisy/bhringraj). Molecular formula: C41H64O13, molecular weight approximately 752.93 g/mol. As a saponin, it contains a hydrophobic triterpenoid aglycone core (oleanolic acid backbone) linked to one or more sugar moieties (glycoside chains), which governs its amphiphilic behavior and biological activity. It contains no meaningful caloric value, protein, fat, or dietary fiber in its isolated form. Bioactive compound concentration in Eclipta prostrata whole plant extract varies significantly by plant part and extraction method, with saponin fractions typically constituting 0.1–2% of dried plant material by weight; Ecliptasaponin A as a distinct isolate represents a minor fraction within that pool. Bioavailability is limited by its high molecular weight and polar sugar chains, which reduce passive intestinal absorption; gut microbial hydrolysis of the glycoside moiety to its aglycone (oleanolic acid) may enhance systemic absorption, a pattern consistent with other triterpenoid saponins. No established therapeutic dosage or standardized concentration data is available in human clinical settings. Solubility is partially water-soluble due to its saponin nature, with enhanced solubility in polar organic solvents.

Preparation & Dosage

No clinically studied dosage ranges are available for Ecliptasaponin A as human trials have not been conducted. The compound is available as a white powder for research purposes, but safe human dosing has not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other saponins, antioxidants, lung support compounds, anti-inflammatory botanicals

Safety & Interactions

No human safety or tolerability data for isolated Ecliptasaponin A currently exists in the published literature. As a saponin, it may share class-level risks including gastrointestinal irritation, nausea, and hemolytic activity at high concentrations observed in some in vitro models. Potential interactions with anticoagulants or immunosuppressants are plausible given its parent plant Eclipta prostrata's known effects on platelet aggregation and immune modulation, though direct interaction studies for Ecliptasaponin A specifically have not been conducted. Pregnant or breastfeeding individuals should avoid use due to a complete absence of safety data in these populations.